Application of rosa roxburghii tratt fruit extract in preparation of medicine or health care product for preventing and treating male lower urinary tract symptoms / prostatic fibrosis

Abstract

The invention provides application of rosa roxburghii tratt fruit extract in preparation of drugs or health care products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis. The invention belongs to the technical field of biological medicines, and provides application of a roxburgh rose extract in preparation of medicines or health care products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis. Animal experiments prove that the rosa roxburghii tratt extract can effectively improve mouse prostate fibrosis and bladder urinary retention caused by high fat diet and relieve lower urinary tract symptoms by regulating lipid metabolism, resisting inflammation, resisting oxidative stress, regulating sex hormone level and inhibiting a TGF-beta / Smad signal channel.

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to the use of a roxburghii roxburghii extract in the preparation of medicines or health products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis. Background Art

[0002] Lower urinary tract symptoms (LUTS) are a common health problem in elderly men. Typical manifestations include obstructive symptoms such as dysuria and incomplete bladder emptying, as well as irritative symptoms such as urgency, dysuria, and nocturia. In severe cases, these symptoms can lead to bladder and renal dysfunction. LUTS are treated with medications of choice, with 5α-reductase inhibitors and α1-receptor antagonists being the two main classes of drugs used. However, approximately 30% of LUTS patients undergo surgical treatment due to unsatisfactory drug efficacy. Recent studies have confirmed that LUTS in middle-aged and elderly men is the result of multiple pathogenic factors. In addition to dynamic and mechanical obstruction, prostate fibrosis can contribute independently or in combination to the development of LUTS. Although the importance of prostate fibrosis in the etiology of LUTS has been recognized, its precise mechanisms of occurrence and development remain unclear, and anti-fibrosis treatment has not yet been incorporated into LUTS treatment strategies.

[0003] Obesity, particularly central obesity, induced by a high-fat diet (HFD) is strongly associated with the development of clinically significant LUTS. Conversely, weight loss is associated with a reduction in LUTS symptoms. Studies have reported that obesity induced by a high-fat diet can promote the formation of lower urinary tract fibrosis in mice; and patients with metabolic syndrome, particularly those with hyperlipidemia, exhibit more severe prostate fibrosis in histopathological specimens.

[0004] Rosa roxburghii Tratt (RRT) is the fruit of the perennial deciduous shrub Rosaceae, widely distributed in the mountainous areas of southwestern and south-central China. RRT is a natural product used for both medicinal and edible purposes. It is rich in nutrients such as amino acids and vitamins, as well as active substances such as polyphenols and flavonoids. It has multiple pharmacological effects, including anti-tumor, antioxidant, anti-inflammatory, antibacterial, anti-atherosclerotic, and hypoglycemic effects. Chinese patent application CN 115844962A discloses the use of roxburghii Tratt extracts / juices in the preparation of preparations for the prevention or treatment of anti-novel coronavirus infection, which can significantly improve lung tissue pathological damage and pulmonary capillary permeability, and inhibit lung tissue inflammatory responses.

[0005] At present, there are no relevant research reports on the use of sea buckthorn extract in the prevention and treatment of male LUTS / prostate fibrosis. Summary of the Invention

[0006] To enrich the existing technology and address the problems existing in the prior art, the present invention provides the use of a roxburghii extract in the preparation of a medicament or health product for preventing and treating male lower urinary tract symptoms / prostate fibrosis. Through animal experiments, the inventors discovered that roxburghii extract can effectively improve prostate fibrosis and intravesical urine retention induced by a high-density urinary disease (HFD) in mice, alleviating lower urinary tract symptoms by regulating lipid metabolism, combating inflammation, resisting oxidative stress, regulating sex hormone levels, and inhibiting the TGF-β / Smad signaling pathway. Based on these findings, the present invention was developed.

[0007] The objects of the present invention will be further illustrated by the following detailed description.

[0008] The present invention provides an application of a roxburghii roxburghii extract in preparing a medicine or health product for preventing and treating male lower urinary tract symptoms / prostatic fibrosis.

[0009] The roxburghii extract provided by the present invention can be used as the sole active ingredient, or in combination with other drugs or health products. Preferably, the roxburghii extract provided by the present invention is used as the sole active ingredient.

[0010] Preferably, the male lower urinary tract symptoms / prostatic fibrosis is male lower urinary tract symptoms / prostatic fibrosis caused by a high-fat diet.

[0011] Preferably, the male is a middle-aged or elderly male.

[0012] Preferably, the preparation method of the roxburghii roxburghii extract comprises the following steps: rotary evaporating the roxburghii stock solution and vacuum freeze-drying to obtain the roxburghii roxburghii extract.

[0013] Preferably, the temperature of the rotary evaporation is 50-65°C.

[0014] More preferably, the temperature of the rotary evaporation is 55-62°C.

[0015] More preferably, the vacuum freeze-drying temperature is -60 to -30° C. More preferably, the vacuum freeze-drying time is 10 to 20 days.

[0016] Preferably, the preparation method of the roxburghii stock solution comprises the following steps: picking roxburghii fruits, washing and drying, removing the cores, and squeezing the juice to obtain the roxburghii stock solution. The roxburghii stock solution can also be obtained by purchasing commercially available roxburghii stock solution products.

[0017] Compared with the prior art, the beneficial effects of the present invention include: through animal experiments, the present invention confirms that the sea buckthorn extract can effectively improve HFD-induced prostate fibrosis and urinary retention in the bladder in mice, and relieve lower urinary tract symptoms by regulating lipid metabolism, anti-inflammation, anti-oxidative stress, regulating sex hormone levels and inhibiting the TGF-β / Smad signaling pathway; furthermore, the present invention provides the application of the sea buckthorn extract in the preparation of drugs or health products for preventing and treating male lower urinary tract symptoms / prostate fibrosis, which broadens the application field of the sea buckthorn extract. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This figure shows the effect of RRT extract on obesity in HFD-fed C57BL / 6J mice.

[0019] Figure 2 This figure shows the effects of RRT extract on prostate inflammation and oxidative stress levels in HFD-fed C57BL / 6J mice.

[0020] Figure 3 This figure shows the effect of RRT extract on serum sex hormones and ERα and AR expression levels in prostate tissue of HFD-fed C57BL / 6J mice.

[0021] Figure 4 This figure shows the effect of RRT extract on the TGF-β / Smad signaling pathway in the prostate tissue of HFD-fed C57BL / 6J mice.

[0022] Figure 5 This figure shows the effects of RRT extract on prostate fibrosis and bladder urine retention in HFD-fed C57BL / 6J mice. DETAILED DESCRIPTION

[0023] The present invention is further described in detail below with reference to the accompanying drawings and embodiments.

[0024] In the present invention, percentage content is understood according to the common meaning in the industry.

[0025] Example 1 Preparation of Rosa roxburghii Extract

[0026] The preparation method of the roxburghii roxburghii extract (RRT extract) comprises: rotary evaporating and vacuum freeze-drying a roxburghii roxburghii stock solution (purchased from Guizhou Peihua Agricultural Science and Technology Development Co., Ltd.) to obtain the roxburghii roxburghii extract; the rotary evaporation temperature is 58°C, and the vacuum freeze-drying temperature is -60°C. The obtained roxburghii roxburghii roxburghii extract (RRT extract) freeze-dried powder is stored at 4°C in a sterilized glass bottle.

[0027] Example 2 Efficacy test of roxburghii extract

[0028] 1. Experimental Materials and Instruments

[0029] 1.1 Experimental Animals

[0030] Thirty 8-week-old male C57BL / 6J mice were obtained from Chongqing Tengxin Biotechnology Co., Ltd. All animal care procedures and experiments were approved by the Laboratory Animal Ethics Committee of Guizhou University (EAE-GZU-2024-E048).

[0031] 1.2 Main instruments and equipment

[0032] Rotary evaporator (Shanghai Hujia Instrument Equipment Co., Ltd.); vacuum freeze dryer (Shandong Olaibo Instrument Co., Ltd.); real-time fluorescence quantitative PCR instrument (Bio-Rad); WIX vertical electrophoresis tank and transfer tank (Weix Technology Co., Ltd.); paraffin dehydrator and embedding machine (Wuhan Junjie Electronics Co., Ltd.); pathology slicer (Shanghai Leica Instrument Co., Ltd.).

[0033] 1.3 Main experimental reagents

[0034] The RRT extract prepared in Example 1; EvoM-MLV reverse transcription premix kit and SYBR GreenPro TaqHS premix qPCR kit (Hunan Aikerui Bioengineering Co., Ltd.); TGF-β1 rabbit anti-polyclonal antibody, Smad2 rabbit anti-polyclonal antibody, and Smad3 mouse anti-polyclonal antibody (Wuhan Sanying Biotechnology Co., Ltd.), p-Smad2 rabbit anti-polyclonal antibody, and p-Smad3 rabbit anti-polyclonal antibody (Chengdu Zhengneng Biotechnology Co., Ltd.); total superoxide dismutase (T-SOD) and malondialdehyde (MDA) kits (Nanjing Jiancheng Bioengineering Institute); estradiol (E2) enzyme-linked immunosorbent assay (ELISA) kit (Wuhan Youxun Life Science Co., Ltd.); testosterone (T) enzyme-linked immunosorbent assay (ELISA) kit (Wuhan Ruixin Bioengineering Co., Ltd.); ERα rabbit anti-polyclonal antibody and AR rabbit anti-polyclonal antibody (Abcam).

[0035] 2. Experimental Methods

[0036] 2.1 Preparation of Rosa roxburghii Extract Reagent

[0037] The RRT extract freeze-dried powder prepared in Example 1 was prepared into a sample solution (mother solution) with a concentration of 800 mg / mL using physiological saline.

[0038] 2.2 Animal grouping and model establishment

[0039] C57BL / 6J mice were randomly divided into three groups, each with 10 mice: a normal diet (ND), a high-fat diet (HFD), and an HFD combined with RRT extract (HFD+RRT). The ND and HFD groups were fed either a normal diet (12.95% of total calories from fat, 24.02% from protein, and 63.03% from carbohydrates) or a high-fat diet (60.93% of total calories from fat, 19.79% from protein, and 19.27% ​​from carbohydrates) for 8 months. After 4 months, starting from the 5th month, mice in the HFD+RRT group received RRT extract (0.2 mL, 200 mg / kg of mouse body weight) via oral gavage once daily, while mice in the ND and HFD groups received normal saline (0.2 mL) once daily. Water was freely available during the experiment. At the end of the experiment (8 months), mice were weighed, and orbital blood was collected before euthanasia. After measuring the diameter of the isolated bladder using a vernier caliper, the prostate specimen was collected and weighed. In addition, mesenteric white adipose tissue (mWAT), inguinal white adipose tissue (iWAT), and epididymal white adipose tissue (eWAT) were harvested and weighed separately. Relative organ weight was determined by dividing organ weight by body weight and multiplying by 100.

[0040] 2.3 Prostate histopathology

[0041] The urethra-prostate complex was fixed in a 10% volume percent neutral formaldehyde solution at room temperature for 24 hours, then dehydrated with ethanol, transparentized with xylene, and finally embedded in paraffin. The embedded urethra-prostate complex (covering the entire prostate) was cut into serial cross-sections (4 μm thick). Afterwards, the sections were stained with hematoxylin-eosin (HE), and the histopathological changes of the prostate and eWAT were observed. The quantitative method for the degree of inflammation in the prostate tissue was as follows: the number of inflammatory cells in 5 randomly selected non-overlapping fields of view in the prostate of each mouse was counted under a 200× magnification field of view; the average value was used as a quantitative indicator of inflammatory infiltration in the prostate tissue.

[0042] 2.4 Real-time quantitative PCR (RT-qPCR)

[0043] RT-qPCR was used to measure the mRNA levels of Il-1β, Il-6, Nf-kb, Cxcl1, Ccl2, Ptgs2, Col1a1 (encoding collagen I), Acta2 (encoding α-SMA), Tgfb1, Esr1 (encoding ERα), Ar, and Gapdh. Total RNA was extracted from mouse prostate using TRIzol reagent. RNA was reverse transcribed into cDNA, and then subjected to RT-qPCR. RT-qPCR was performed using the SYBR Green Premix Pro Taq HS qPCR Kit. The mRNA levels of 2- ΔΔ The relative mRNA levels were calculated by Ct.

[0044] 2.5 Antioxidant index detection

[0045] The total superoxide dismutase (T-SOD) and malondialdehyde (MDA) in mouse prostate tissue were detected using the kit provided by Nanjing Jiancheng Bioengineering Research Institute according to the instructions.

[0046] 2.6 Serum hormone testing

[0047] The E2 enzyme-linked immunosorbent assay kit provided by Wuhan Youxun Life Science Co., Ltd. and the T enzyme-linked immunosorbent assay kit provided by Wuhan Ruixin Bioengineering Co., Ltd. were used to detect the E2 and T levels in serum according to the requirements of the instructions.

[0048] 2.7 Western blotting (WB)

[0049] After total protein extraction, proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred to a PVDF membrane. After blocking with 5% skim milk powder, the membranes were excised and incubated with the primary antibody overnight at 4°C. After washing, the membranes were incubated with the secondary antibody for 2 hours at room temperature. Protein signals were detected using an ECL chemiluminescent substrate. Signal intensity on the membranes was quantified using a computer-assisted imaging system and normalized to the corresponding GAPDH signal.

[0050] 2.8 Immunohistochemistry (IHC)

[0051] Estrogen receptor α (ERα) and androgen receptor (AR) staining was performed using the following procedure: sections were treated with blocking solution at room temperature for 30 minutes, followed by overnight incubation at 4°C with anti-ERα antibodies (1:300 dilution) and anti-AR antibodies (1:100 dilution). After thorough rinsing with Tris-NaCl buffer, sections were incubated with biotinylated goat anti-rabbit IgG (1:200 dilution in Tris-NaCl buffer) for 60 minutes at room temperature. Sections were then incubated with streptavidin-biotinylated enzyme complex and 3,3'-diaminobenzidine (DAB). ERα and AR staining was scored based on the percentage of positive cells and staining intensity. The percentage of positive cells was expressed as a four-point scale: <5% = 0, 6% to 25% = 1, 26% to 50% = 2, 51% to 75% = 3, and >75% = 4. Staining intensity was scored as follows: no staining = 0, weak staining = 1, moderate staining = 2, and strong staining = 3. The histological score (H-score) of each sample was determined according to the following formula: H-score = percentage score × intensity score. The expression of ERα and AR was semi-quantitatively analyzed using the H-score.

[0052] 2.9 Masson trichrome staining

[0053] The sections were placed in Weigert's hematoxylin for 10 minutes. After washing with distilled water, the sections were stained in Masson's trichrome solution for 10 minutes. The sections were rinsed in 95% ethanol, dehydrated, cleared, and mounted. Collagen fibers and smooth muscle were stained blue and red, respectively. The relative area of ​​collagen fibers was quantified as follows: 4 non-overlapping fields were randomly selected from each mouse prostate at 200× magnification. The area of ​​the blue-stained area between the prostate acini and around the glands was measured using ImageJ software to calculate the relative area of ​​collagen fibers. The average value was used as the quantitative index of collagen fibers in the prostate of each mouse.

[0054] 2.10 Statistical Analysis of Data

[0055] The data of each group are expressed as mean ± standard deviation (mean ± SD). SPSS software version 20.0 (10.00) was used to perform one-way analysis of variance (ANOVA) and t-test to determine whether there were statistically significant differences. P < 0.05 indicated a statistically significant difference.

[0056] 3. Experimental Results

[0057] The results of the effect of RRT extract on obesity in HFD-fed C57BL / 6J mice are shown in the figure. Figure 1 As shown. Among them, Figure 1 -A is the weight curve of mice in different groups changing over time; Figure 1-B is the morphological observation of mice in different groups after the experiment; Figure 1 -C is the weight results of mice in different groups after the experiment; Figure 1 -D is a schematic diagram of epididymal white adipose tissue in different groups of mice after the experiment; Figure 1 -E is the relative organ weight of white fat in different groups of mice after the experiment. Figure 1 As shown, at 4 months, the body weights of mice in the HFD and HFD+RRT groups were significantly higher than those in the ND group, while there was no significant difference in body weight between the HFD and HFD+RRT groups. After 4 months, the body weight of mice in the HFD+RRT group gradually decreased compared with the HFD group. By the end of the experiment, the body weight and relative weight of white adipose tissue (WAT) (including mWAT, iWAT, and eWAT) of mice in the HFD group were significantly increased compared with those in the ND group. In contrast, treatment with RRT extracts significantly decreased the body weight and relative WAT weights (mWAT, iWAT, and eWAT) of mice in the HFD+RRT group. These results indicate that RRT extract treatment can significantly ameliorate obesity induced by HFD feeding in C57BL / 6J mice.

[0058] The results of the effects of RRT extract on prostate inflammation and oxidative stress levels in HFD-fed C57BL / 6J mice are shown in the figure. Figure 2 As shown. Among them, Figure 2 -A is the HE staining observation and statistical diagram of prostate tissues of mice in different groups; Figure 2 -B is the relative expression level of Il-1β and other mRNA in the prostate of mice in different groups; Figure 2 -C is the result graph of T-SOD and MDA content in the prostate of mice in different groups. Figure 2 As shown, compared with the ND group, diffuse or focal inflammatory cell infiltration was observed between prostate acini in HFD mice, a finding significantly improved in RRT extract-treated HFD mice. RT-qPCR results revealed that the relative mRNA expression levels of Il-1β, Il-6, Ptgs2, Cxcl1, Ccl2, and Nf-κb were significantly increased in the prostates of HFD mice compared with those of ND mice, while RRT extract treatment effectively reduced the expression of these inflammatory mediators in the prostates of HFD mice. Furthermore, compared with ND mice, T-SOD levels were decreased and MDA levels were increased in the prostates of HFD mice. Conversely, T-SOD levels were increased and MDA levels were decreased in the prostates of HFD+RRT mice. These results suggest that RRT extract can reduce prostate inflammation and oxidative stress in HFD-fed C57BL / 6J mice.

[0059] The results of the effects of RRT extract on serum sex hormones, ERα and AR expression levels in prostate tissues of HFD-fed C57BL / 6J mice are shown in the figure. Figure 3 As shown. Among them, Figure 3 -A is the result graph of serum E2 and T levels in mice of different groups; Figure 3 -B is the mRNA expression results of ERα and AR in the prostate of mice in different groups; Figure 3 -C is the IHC staining image of ERα and AR in mice of different groups; Figure 3 -D is the protein expression results of ERα and AR in the prostate of mice in different groups. Figure 3 As shown, compared with ND mice, serum E2 levels were increased and T levels were decreased in HFD mice. However, compared with the HFD group, serum E2 levels were decreased and T levels were increased in HFD mice treated with RRT extract. Furthermore, ERα and AR mRNA and protein expression in the prostate of each group of mice was examined by RT-qPCR and IHC, respectively. RT-qPCR results showed that Esr1 (encoding ERα) mRNA levels were increased in the prostate of HFD mice compared with the ND group, while RRT extract treatment significantly reduced Esr1 mRNA expression in the prostate. No significant changes in AR mRNA were observed in the three groups of mice. IHC images showed that ERα-positive cells were located in the fibromuscular layer surrounding the acini and in the stromal cells between prostate acini, while AR-positive cells were found within the acinar lumen and ductal epithelium. Compared with the ND group, the HFD group showed more ERα-positive interacinar stromal cells. Although ERα expression was lower in the RRT extract-treated group than in the HFD group, the difference was not statistically significant. Consistent with the Arm RNA levels, there was no significant difference in AR protein expression among the three groups of mice. The above results indicate that RRT extract can improve the serum sex hormones and ERα and AR expression levels in prostate tissue of HFD-fed C57BL / 6J mice.

[0060] The results of the effect of RRT extract on the TGF-β / Smad signaling pathway in the prostate tissue of HFD-fed C57BL / 6J mice are shown in the figure. Figure 4 As shown. Figure 4 As shown in the results, compared with the ND group, the expression of TGF-β1, p-Smad2 / Smad2 and p-Smad3 / Smad3 in the prostate tissue of mice in the HFD group was significantly increased; however, after RRT treatment, the expression of TGF-β1, p-Smad2 / Smad2 and p-Smad3 / Smad3 was significantly downregulated, indicating that RRT extract effectively inhibited the TGF-β / Smad signaling pathway in the prostate tissue of HFD-fed C57BL / 6J mice.

[0061] The results of the effects of RRT extract on prostate fibrosis and bladder urinary retention in HFD-fed C57BL / 6J mice are shown in the figure. Figure 5 As shown. Among them, Figure 5-A is the observation diagram of prostate tissue morphology and statistical diagram of prostate-related weight and bladder diameter of mice in different groups; Figure 5 -B is the HE staining image and Masson trichrome staining of mice in different groups and the statistical graph of relative collagen fiber area; Figure 5 -C is the expression results of Acta2, Col1a1 and Tgfb1 mRNA in the prostate of mice in different groups. Figure 5 As shown, there were no significant differences in relative prostate weights among the three groups of mice. However, compared with the ND group, most mice in the HFD group exhibited increased bladder diameter and urinary retention. In contrast, after treatment with RRT extract, only a few mice in the HFD+RRT group exhibited mild urinary retention, and their bladder diameters were significantly reduced. Masson trichrome staining revealed that the relative collagen fiber area in the HFD group was significantly greater than that in the ND group. In contrast, treatment with RRT extract significantly improved the collagen fiber area in the prostates of HFD+RRT mice. Furthermore, RT-qPCR results revealed increased mRNA expression levels of Col1a1 and Tgfb1 in the prostates of HFD mice compared with ND mice. However, treatment with RRT extract significantly decreased Col1a1 and Tgfb1 mRNA expression in the prostates of HFD+RRT mice. This suggests that RRT extract can effectively ameliorate urinary retention and prostate fibrosis in HFD-fed C57BL / 6J mice.

[0062] From the perspective of overall experiments, the present invention uses experimental methods such as HE staining, Masson trichrome staining, IHC staining, WB and RT-qPCR to conclude that the sea buckthorn extract can reduce obesity in mice induced by a high-fat diet, improve prostate tissue inflammation and oxidative stress levels, and inhibit the TGF-β / Smad signaling pathway in prostate tissue. This indicates that the sea buckthorn extract can effectively improve HFD-induced prostate fibrosis and urinary retention in the bladder in mice through the above pathways, and relieve lower urinary tract symptoms.

[0063] The above is a further detailed description of the present invention in conjunction with specific preferred embodiments, and the specific implementation of the present invention should not be considered to be limited to these descriptions. For those skilled in the art of the present invention, without departing from the concept of the present invention, several simple deductions or substitutions can be made, which should be considered to fall within the scope of protection of the present invention.

Claims

1. Use of a roxburghii extract in the preparation of a medicine or health product for preventing and treating male lower urinary tract symptoms / prostatic fibrosis.

2. Use of the roxburghii extract according to claim 1 in preparing medicines or health products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The male lower urinary tract symptoms / prostatic fibrosis are male lower urinary tract symptoms / prostatic fibrosis caused by a high-fat diet.

3. Use of the roxburghii extract according to claim 1 in preparing medicines or health products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The male is a middle-aged or elderly man.

4. Use of the roxburghii extract according to any one of claims 1 to 3 in the preparation of a medicament or health product for preventing and treating lower urinary tract symptoms / prostatic fibrosis in men, characterized in that: The preparation method of the roxburghii roxburghii extract comprises the following steps: rotary evaporating the roxburghii stock solution and vacuum freeze-drying the roxburghii roxburghii extract to obtain the roxburghii roxburghii extract.

5. Use of the roxburghii extract according to claim 4 in preparing medicines or health products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The temperature of the rotary evaporation is 50-65°C.

6. Use of the roxburghii extract according to claim 5 in preparing medicines or health products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The temperature of the rotary evaporation is 55-62°C.

7. Use of the roxburghii extract according to claim 4 in the preparation of a medicine or health product for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The vacuum freeze-drying temperature is -80 to -20°C.

8. Use of the roxburghii extract according to claim 7 in the preparation of a medicine or health product for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The vacuum freeze-drying temperature is -60 to -30°C.

9. Use of the roxburghii extract according to claim 4 in preparing a medicine or health product for preventing and treating male lower urinary tract symptoms / prostatic fibrosis, characterized in that: The preparation method of the roxburghii stock solution comprises the following steps: picking roxburghii fruits, washing and drying the fruits, removing the cores, and squeezing the juice to obtain the roxburghii stock solution.

Images